IP Library Granted Patent US 9,073,882
Granted Patent B2
US 9,073,882 · App. 13/881,008 · Granted Jul 7, 2015

Inhibitors of the renal outer medullary potassium channel

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,073,882
App. No.
13/881,008
Granted
Jul 7, 2015
Kind
B2
Abstract

This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

Claims (160)

1. A compound having structural Formula I:

or a pharmaceutically acceptable salt thereof wherein:

represents:

R 7 is selected from —H, —F, —CH 3 , —CF 3 , —CHF 2 , —CH 2 F, —CH 2 OH, cyclopropyl or —CH 2 C(═O)O—CH 3 , or R 7 represents di-substitution on a single carbon with two of —F or two of —CH 3 ;

Z 1 is selected from:

Z 2 is selected from:

one of W 1 and W 2 is N and the other is CH;

R 1 and R 2 are each independently selected from —H, —F, —Cl, —Br, —C 3 —C 6 cycloalkyl, —OR 8 , —SR 8 , —SOR 8 , —SO 2 R 8 , —(CH 2 ) n OR 8 or —C 1-6 alkyl optionally substituted with 1-3 of —F;

one of R 3a and R 3b is selected from —CN, —NO 2 or tetrazoly, and the other is R 3c wherein R 3c selected from —H, —F, —Cl, —Br, —CH 3 , —S—CH 3 , —NH—CH 3 , —O-cyclopropyl or —OC 1-3 alkyl optionally substituted with 1-3 of —F;

one of R 4a and R 4b is selected from CN, —NO 2 or tetrazolyl, and the other is R 4c wherein R 4c is selected from —H, —F, —Cl, —Br, —CH 3 , —S—CH 3 , —NH—CH 3 , —O-cyclopropyl or —OC 1-3 alkyl optionally substituted with 1-3 of —F;

R a , R aa , R b and R bb are each independently selected from —H, —F, —Cl, —CH 3 optionally substituted with 1 to 3 of —F, or —OCH 3 optionally substituted with 1 to 3 of —F;

R c and R d are each independently selected from —H, —F, —Cl, —C 1-6 alkyl optionally substituted with 1 to 3 of —F, —C 3-6 cycloalkyl or —OC 1-6 alkyl optionally substituted with 1 to 3 of —F;

R e and R f are each independently selected from —H or —CH 3 ;

X and X 1 are each independently selected from —H or —C 1-6 alkyl,

or X 1 is joined together with Z 1 and the carbon to which both are attached to form a fused ring system selected from:

Y and Y 1 are each independently selected from —H or —C 1-6 alkyl,

or Y 1 is joined together with Z 2 and the carbon to which both are attached to form a fused ring system selected from

R 5 and R 6 are each independently selected from —H, —C 1-6 alkyl or —C(O)OC 1-3 alkyl;

and

R 8 is selected from —C 1-6 alkyl or —C 3-6 cycloalkyl.

2. The compound of claim 1 wherein:

Z 1 is selected from:

Z 2 is selected from:

X and X 1 are each independently selected from —H or —C 1-6 alkyl;

Y and Y 1 are each independently selected from —H or —C 1-6 alkyl,

or Y 1 is joined together with Z 2 and the carbon to which both are attached to form a fused ring system selected from:

R 5 is selected from —H, —CH 3 , —C 1-6 alkyl or —C(O)OC 1-3 alkyl; and

R 6 is selected from —H, —CH 3 , —C 1-6 alkyl or —C(O)OC 1-3 alkyl,

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 wherein

R 7 is —H;

R 1 and R 2 are independently selected from —H or —CH 3 ;

R a and R b are each independently selected from —H, —F, —Cl, —CH 3 optionally substituted with 1 to 3 of —F, or —OCH 3 optionally substituted with 1 to 3 of —F;

R aa and R bb are each independently selected from —H or —F

R c and R d are each independently selected from —H, —F, —Cl, —CH 3 optionally substituted with 1 to 3 of —F, or —OCH 3 optionally substituted with 1 to 3 of —F;

R 5 is selected from —H or —CH 3 ;

R 6 is selected from —H or —CH 3 ;

X, X 1 and Y are each —H; and

Y 1 is —H, or Y 1 is joined together with Z 2 and the carbon to which both are attached to form a fused ring system as defined in claim 1 ;

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 selected from:

1,4-Bis[2-(4-nitrophenyl)ethyl]piperazine;

2-Methoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Methoxy-4-[2-[4-[2-(4-methyl-1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]benzonitrile;

5,5′-(Piperazine-1,4-diyldiethane-2,1-diyl)bis(4-methyl-2-benzofuran-1(3H)-one);

5,5′-(Piperazine-1,4-diyldiethane-2,1-diyl)bis(2-benzofuran-1(3H)-one

2-Ethoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

4-Fluoro-2-methoxy-3-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

4-Methyl-5-(1-(4-(2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)propan-2-yl)isobenzofuran-1(3H)-one;

2-Methoxy-4-(2-{4-[2-(3-methyl-1-oxo-3,4-dihydro-1H-isochromen-6-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2,2-Dimethyl-1,4-bis[2-(4-nitrophenyl)ethyl]piperazine;

4-Methyl-5-[2-[4-[2-[6-(tetrazol-1-yl)-3-pyridyl]ethyl]piperazin-1-yl]ethyl]-3H-isobenzofuran-1-one;

2-Methoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]-2-(trifluoromethyl)piperazin-1-yl}ethyl)benzonitrile;

4-(2-{4-[2-(4-Methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)naphthalene-1-carbonitrile;

4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

(3S,3'S)-6,6′-(Piperazine-1,4-diyldiethane-2,1-diyl)bis(3-methyl-3,4-dihydro-1H-isochromen-1-one);

2-(Methylamino)-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Fluoro-4-[2-[4-[2-(1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]benzonitrile;

2-(Cyclopropyloxy)-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

3-Chloro-2-fluoro-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile; or

4-Fluoro-2-methoxy-3-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 selected from:

1,4-Bis[2-(4-nitrophenyl)ethyl]piperazine;

4,4′-(Piperazine-1,4-diyldiethane-2,1-diyl)dibenzonitrile;

2-Methoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Methoxy-4-[2-[4-[2-(4-methyl-1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]benzonitrile;

5,5′-(Piperazine-1,4-diyldiethane-2,1-diyl)bis(4-methyl-2-benzofuran-1(3H)-one);

5,5′-(Piperazine-1,4-diyldiethane-2,1-diyl)bis(2-benzofuran-1(3H)-one;

2-Ethoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

4-Fluoro-2-methoxy-3-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

4-Methyl-5-(1-(4-(2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)propan-2-yl)isobenzofuran-1(3H)-one; or

4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprised of a compound of claim 1 and a pharmaceutically acceptable carrier.

7. A compound selected from:

1,4-Bis[2-(4-nitrophenyl)ethyl]piperazine;

1-[2-(4-Nitrophenyl)ethyl]-4-[2-(5-nitropyridin-2-yl)ethyl]piperazine;

4-(2-{4-[2-(4-Nitrophenyl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-(Fluoromethyl)-1,4-bis[2-(4-nitrophenyl)ethyl]piperazine;

4,4′-(Piperazine-1,4-diyldiethane-2,1-diyl)dibenzonitrile;

2-Methyl-1,4-bis[2-(4-nitrophenyl)ethyl]piperazine;

Methyl(2S)-3-(4-nitrophenyl)-2-{4-[2-(4-nitrophenyl)ethyl]piperazin-1-yl}propanoate;

2,2-Dimethyl-1,4-bis[2-(4-nitrophenyl)ethyl]piperazine;

2-Cyclopropyl-1,4-bis[2-(4-nitrophenyl)ethyl]piperazine;

2-(Difluoromethyl)-1,4-bis[2-(4-nitrophenyl)ethyl]piperazine;

{1,4-Bis[2-(4-nitrophenyl)ethyl]piperazin-2-yl}methanol;

1-[2-(4-Nitrophenyl)ethyl]-4-[2-(4-nitrophenyl)propyl]piperazine;

1-[2-(4-Nitrophenyl)ethyl]-4-{2-[4-nitro-2-(trifluoromethyl)phenyl]ethyl}piperazine;

1-[1-Methyl-2-(4-nitrophenyl)ethyl]-4-[2-(4-nitrophenyl)ethyl]piperazine;

1,4-Bis[1-methyl-2-(4-nitrophenyl)ethyl]piperazine;

Methyl {1,4-bis[2-(4-nitrophenyl)ethyl]piperazin-2-yl}acetate;

2-Methoxy-4-(2-{4-[2-(4-nitrophenyl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

3-Methyl-4-(2-{4-[2-(4-nitrophenyl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Methyl-4-(2-{4-[2-(4-nitrophenyl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2,6-Difluoro-4-(2-{4-[2-(4-nitrophenyl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

3-Methoxy-4-(2-{4-[2-(4-nitrophenyl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Fluoro-4-(2-{4-[2-(4-nitrophenyl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

1-((4-(2-(1-Oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)methyl)-2,3-dihydro-1H-indene-4-carbonitrile;

2-Methoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

4-({4-[2-(1-Oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}methyl)-3,4-dihydro-2H-chromene-7-carbonitrile;

5-({4-[2-(1-Oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}methyl)-5,6,7,8-tetrahydronaphalene-2-carbonitrile;

2-Fluoro-4-[2-[4-[2-(1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]benzonitrile;

2,5-Difluoro-4-[2-[4-[2-(1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]benzonitrile;

2-Bromo-4-[2-[4-[2-(1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]benzonitrile;

2-Methoxy-4-[2-[4-[2-(4-methyl-1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]benzonitrile;

5-[2-[4-[2-[6-(Tetrazol-1-yl)-3-pyridyl]ethyl]piperazin-1-yl]ethyl]-3H-isobenzofuran-1-one;

4-Methyl-5-[2-[4-[2-[6-(tetrazol-1-yl)-3-pyridyl]ethyl]piperazin-1-yl]ethyl]-3H-isobenzofuran-1-one;

2-Methoxy-4-[1-methyl-2-[4-[2-(1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]benzonitrile;

2-Methoxy-4-[1-methyl-2-[4-[2-(4-methyl-1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]benzonitrile;

2-Methoxy-4-[2-[4-[2-(4-methyl-1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]propyl]benzonitrile;

4-[1,1-Dimethyl-2-[4-[2-(4-methyl-1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-2-methoxy-benzonitrile;

2-Methoxy-4-[2-[4-[2-(1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]propyl]benzonitrile;

2-(Difluoromethoxy)-4-[2-[4-[2-(4-methyl-1-oxo-3H-isobenzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]benzonitrile;

5-Fluoro-3-({4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}methyl)-3,4-dihydro-2H-chromene-7-carbonitrile;

2-Methoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]-3-(trifluoromethyl)piperazin-1-yl}ethyl)benzonitrile;

5-Fluoro-2-methoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

5-Fluoro-2-methoxy-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

4,4′-(Piperazine-1,4-diyldiethane-2,1-diyl)bis(5-fluoro-2-methoxybenzonitrile);

2-Methoxy-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)propyl]piperazin-1-yl}ethyl)benzonitrile;

2-Methoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]-2-(trifluoromethyl)piperazin-1-yl}ethyl)benzonitrile;

2-Methoxy-4-(2-{4-[2-(3-methyl-1-oxo-3,4-dihydro-1H-isochromen-6-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

(3 S,3′S)-6,6′-(Piperazine-1,4-diyldiethane-2,1-diyl)bis(3-methyl-3,4-dihydro-1H-isochromen-1-one);

5,5′-(Piperazine-1,4-diyldiethane-2,1-diyl)bis(4-methyl-2-benzofuran-1(3H)-one);

2-(Methylthio)-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile:

5-Chloro-2-methoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-(Methylamino)-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-(Difluoromethoxy)-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-(Cyclopropyloxy)-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

5-(2-{4-[2-(4-Nitrophenyl)ethyl]piperazin-1-yl}ethyl)-2-benzofuran-1(3H)-one;

5,5′-(Piperazine-1,4-diyldiethane-2,1-diyl)bis(2-benzofuran-1(3H)-one;

2-Trifluoromethoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Trifluoromethoxy-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Chloro-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Chloro-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

3-Fluoro-2-methoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

3-Fluoro-2-methoxy-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

4-(2-{4-[2-(4-Methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)naphthalene-1-carbonitrile;

2,3,5-Trifluoro-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Ethoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Ethoxy-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

5-Chloro-2-fluoro-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

5-Chloro-2-fluoro-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

5-Chloro-2-methoxy-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Fluoro-3-methyl-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Fluoro-3-methyl-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Methoxy-3-methyl-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

2-Methoxy-3-methyl-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

3-Chloro-2-fluoro-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

3-Chloro-2-fluoro-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

3-Chloro-2-methoxy-4-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

3-Chloro-2-methoxy-4-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

4-Fluoro-2-methoxy-3-(2-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

4-Fluoro-2-methoxy-3-(2-{4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

4-({4-[2-(4-Methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}methyl)-3,4-dihydro-2H-chromene-7-carbonitrile;

5-Fluoro-3-({4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}methyl)-3,4-dihydro-2H-chromene-7-carbonitrile;

5,5′-(Piperazine-1,4-diyldipropane-1,3-diyl)bis(4-methyl-2-benzofuran-1(3H-one);

4-Methyl-5-(1-(4-(2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)propan-2-yl)isobenzofuran-1(3H)-one;

4-(2-{4-[2-(1-Oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}ethyl)benzonitrile;

or a pharmaceutically acceptable salt thereof.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2013
From: TANG, HAIFENG; PASTERNAK, ALEXANDER; WALSH, SHAWN P.; YANG, LIHU; PIO, BARBARA; SHAHRIPOUR, AURASH; TEUMELSAN, NARDOS
To: MERCK SHARP & DOHME CORP.
Reel/Frame 030916/0410 →